YEAR-END REPORT 2006

• The Group’s revenues from sales of goods and royalties amounted to SEK 1,303.7 (976.0) million, an increase of 34 percent.

• Operating income amounted to SEK 300.0 (111.7) million.

• Net income after tax amounted to SEK 212.4 (77.1) million.

• Earnings per share after full dilution were SEK 2.14 (0.78).

• Net income after tax for the fourth quarter amounted to SEK 25.7 (30.3) million.

• Collaboration agreement concerning the development and commercialization of botulinum toxin products, entered into with Medy-Tox Inc. in February 2007.

• Q-Med’s product for fecal incontinence, SOLESTA, approved for sales in Europe.

• The Board has adopted a new dividends policy, whereby it is proposed that approximately 50 percent of profit after tax is paid out as a regular dividend.

• The Board intends to propose to the AGM a dividend of SEK 2 per share, of which SEK 1 is regular dividend and SEK 1 extra dividend.

Queries should be addressed to:
Erika Kjellberg Eriksson, Vice President and CFO
Tel: + 46 70-974 90 20.


Coming reports:
Interim report January – March 2007
May 3, 2007

Interim report January – June 2007
July 26, 2007

Interim report January – September 2007
October 23, 2007

Annual General Meeting:
May 3, in Uppsala


Chairman of the election committee:
Robert Wikholm, robert.wikholm@vinge.se

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.

Subscribe

Documents & Links